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Maternal infections that are transmissible in utero at several stages of the pregnancy can be caused by many organisms, of which the members of the TORCH 
complex, namely, Toxoplasma gondii, rubella, Cytomegalovirus 
(CMV), and herpes simplex virus (HSV) occupy prominent 
positions [1]. These infections are associated with inadvertent 
outcomes such as multiple infections, abortions, infertility, 
fetal deaths, stillbirths, congenital malformations, and other 
reproductive failures, especially when they are acquired 
during the first trimester of pregnancy [2]. The diagnosis 
of acute TORCH infection in pregnant women, usually 
established by demonstration of seroconversion in paired sera 
or by demonstration of specific IgM antibodies, is pertinent 
for management of such infections [3,4]. TORCH screening 
in the antenatal period helps to identify high-risk mothers who 
alone or along with developing fetus are at an increasing risk of 
complications during/after pregnancy and birth. Infection may 
be asymptomatic or mild in the mother, but the outcome can be 
grave for the developing fetus [5]. In the absence of national 
screening program for TORCH, serological detection for TORCH 
infections during pregnancy remains the only means of revealing 
such infections [6-8]. Often treatment of maternal infections has 
no impact on the fetal outcome. Hence, the knowledge of these 
diseases will not only help obstetrician’s counsel mothers on 
preventive measures to avoid these infections but will also aid 
in guiding parents on the potential for adverse fetal outcomes 
when these infections are present. Only few published data from 
India describing the seroprevalence of specific IgM antibodies to 
TORCH agents exist in this part of Northern India. This study 
was undertaken to look for serological evidence of the acute 
TORCH infections in high-risk pregnant women, by establishing 
the presence of specific IgM antibodies.
MATERIAL AND METHODS
A total of 240 pregnant women with previous unfavorable fetal 
outcome or bad obstetric history (BOH) attending the antenatal 
clinic of our tertiary care teaching hospital from November 
2011 to October 2016 were included in the study. Cases with 
hypertension, diabetes mellitus, eclampsia of pregnancy, and Rh 
incompatibility were excluded from the study. Detailed clinical 
history, physical examination, and conventional laboratory 
investigations were conducted. This hospital caters mostly to 
the low socioeconomic class from this part of Northern India. 
The subjects mostly belonged to rural strata. Approximately 
2–3 ml of blood was collected aseptically, and serum samples 
were analyzed for specific IgM antibodies to T. gondii, rubella, 
CMV, and combined HSV-1 and 2. All tests were capture 
enzyme-linked immunosorbent assay (ELISA) done according 
to manufacturer’s instructions. All kits were from DIA.PRO 
Diagnostic Bioprobes SRL, Italy, having a sensitivity >98% and 
specificity >98%. All the patients, whose sera showed equivocal 
results, were retested after collecting fresh blood samples 
2 weeks later.
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RESULTS
Overall seropositivity for IgM antibodies against T. gondii, rubella, 
CMV, and HSV for either a single organism or in combination, in 
the present study, was found to be 98.8% (n=237). Seropositivity 
for T. gondii was found to be 24.2% (n=58), rubella 9.2% (n=22), 
CMV 53.8% (n=129), and 11.7% (n=28) were seropositive 
for combined HSV-1 and 2 infections. On the whole, highest 
seropositivity (47.5%) was seen in the age group of 21–30 years. 
The proportion of seropositives for Toxoplasma (p=0.004), rubella 
(p=0.028), and HSV (p=0.001) was higher in the age group of 
<20 years as compared to other age groups, and this finding was 
statistically significant (Fig. 1). However, CMV seropositivity 
was found to be highest in the age group of 21–30 years and 
the association with age was statistically significant (p≤0.001). 
Multiple infections as compared to none or single infections were 
also more common (p≤0.000) in the <20 years of age group. 
Overall, 15.4% (37) of women were seropositive for coinfections, 
14.5% (35) were dual infection while two cases (0.9%) had a 
triple infection (Table 1).
DISCUSSION
In the present study, seroprevalence of TORCH infections in high-
risk pregnant females was found to be 98.8% contrasting with 
the 13.8% seroprevalence reported by Padmavathy et al. from 
Bengaluru [4]. However, Kaur et al. from Central Delhi reported 
high prevalence (93.4%), emphasizing the need for TORCH 
screening and adding further impetus to the need of immunization 
to evade the otherwise foreseeable fetal outcome [5].
It was observed that, in general, seroprevalence of TORCH 
infections was more common in 21–30 years age group analogous 
with a study from Gujarat, Bengaluru, Delhi, and Nepal probably 
because this is the most common childbearing age group [1,4,5,9]. 
In contrast to a study from Varanasi (19–25 years) and Bengaluru 
(25–30 years), the current study found a statistically significant 
association of seropositivity to T. gondii, rubella, and HSV with 
the <20 years age group [4,10]. A study from Croatia reports 
Toxoplasma seropositivity rate of 15% seen in the age group 
>40 years, highlighting the fact high-risk antenatal woman in all 
groups should be screened for TORCH infections to define the 
susceptible population.
Seroprevalence of Toxoplasma IgM among high-risk pregnant 
women in different countries of the world had been found to range 
between 7.7 and 76.7% with Nigeria topping the list at 76%, closely 
followed by Brazil (50–75%), while India stands at 55% [11-13]. 
Our finding of 24% seroprevalence in the present study is in tune 
with a study from Gujarat (23.4%) [14]. Prevalence of IgM-positive 
Toxoplasma infection ranges from 9 to 55% in Indian studies [15]. 
Some of them proved that persistence of encysted forms of 
T. gondii in chronically infected uteri and their ruptures during 
placentation leads to infection of the baby in the first trimester 
and often to recurrent miscarriages [13,14,16]. As it remains the 
only TORCH infection which is treatable and completely curable 
in pregnancy by a single dose of spiramycin, toxoplasmosis 
should be diagnosed early in the antenatal period and treated to 
prevent complications. Women who show seroconversion during 
their pregnancies should be closely monitored clinically during 
their subsequent pregnancies and should be advised to avoid raw/
undercooked meat and unpasteurized milk and to keep away from 
pets, mainly cats. Toxoplasmosis can also lead to infertility as has 
been documented from China and Palestine [17]. Zhou found that 
Toxoplasma was common in infertile couples possibly related to 
anti-sperm antibodies which were higher in Toxoplasma-infected 
couples [18].
The WHO estimates that, worldwide, more than 1 lakh 
children are born with congenital rubella syndrome (CRS) 
each year, most of them in developing countries [16,19]. 
Seroepidemiological studies have shown that 10–20% of the 
women in the childbearing ages in India are susceptible to 
rubella infection [20,21]. On the other hand, the risk of the CRS 
following a maternal infection is documented to range from 5 
to 50% in various studies, with increased severity if acquired in 
the first trimester of pregnancy [22]. The IgM seropositivity of 
rubella in India and other countries ranges between 4.7 and 28.6% 
in women of reproductive age groups. The present study reports a 
seropositivity of 10.4% for acute rubella infections. This is higher 
when compared to studies from South India (3–4.5%) [3,23]. 
However, studies from northern and western zones of India 
document acute infection rate up to 26% [13,24]. The paradox 
Table 1: Prevalence of mixed etiology of TORCH infection
Age group in years n=number of cases 
recruited(%)
Only mono infected 
n (%)
Infected with two 
agents n (%)




<20 n=36 (15) 22 (61.1) 13 (36.1) 0 (0) 1 (2.8)
21–30 n=117 (48.8) 104 (88.9) 12 (10.3) 1 (0.9) 0 (0)
31–40 n=56 (23.3) 45 (80.4) 9 (16.1) 1 (18) 1 (18)
>40 n=31 (13) 29 (93.5) 1 (3.2) 0 (0) 1 (3.2)
Total (n=240) 200 (83.3) 35 (14.5) 2 (0.8) 3 (1.3)
Figure 1: Age-specific distribution of seropositive TORCH cases
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lies in the fact that a large proportion of the cases (nearly 50%) 
are subclinical and that clinical diagnosis is often unreliable [20]. 
Moreover, there is a considerable variation in the prevalence 
of the rubella-specific IgG antibodies among the women of the 
childbearing ages, with studies suggesting a prevalence of 71.3% 
rubella immunity, thus leaving about one-third of the women 
susceptible to the rubella infection [21,22]. The screening for the 
rubella immunity was not done in this study. Further, the history 
of the vaccination against rubella could not be gathered from the 
study population. However, on the basis of the low socioeconomic 
status and poor educational background, it may be presumed 
that most of our subjects had not been previously vaccinated. 
Hence, vaccination of rubella at 1.5 years with measles, mumps, 
and rubella or at 14–15 years with rubella vaccine alone must 
be considered a priority to prevent subsequent maternal and fetal 
risk.
Primary CMV infection in pregnancy has a higher incidence, 
especially in women of rural population. This infection is usually 
asymptomatic, thus posing difficulty in clinical diagnosis. In 
the present study, the seropositive rate of CMV IgM in high-
risk pregnant women was 52.9% which is markedly higher 
when compared to studies from Rajkot (4.7%) and Mumbai 
(8.4%) [1,14]. Studies from South India report an extremely low 
(0.8%) IgM seropositivity probably due to smaller sample size in 
their study [3]. However, a seroprevalence rate of 33–35% has 
been documented from Bengaluru and Varanasi [4,10]. Highest 
CMV seropositivity among the TORCH agents observed in the 
current study was similar to the Bengaluru study [4]. Pregnancy 
may reactivate the latent CMV leading to further reproductive 
wastages. Although serological surveys in different parts of India 
document 80–90% prevalence of IgG CMV antibodies in women 
of childbearing age [25], reinfection with a variant strain of 
CMV can cause infections even in the presence of detectable IgG 
levels [26]. The high seropositivity in the present study may be 
due to either primary infection in our economically less privileged 
population or reinfection with a variant strain of virus. Hence, 
screening of pregnant females for CMV-specific IgM antibodies 
is beneficial in alerting the obstetrician and pediatrician regarding 
possible infection of mother and newborn. The suspected 
newborn can further be subjected to the testing for CMV-specific 
IgM antibodies. Thus, timely medical treatment can be started to 
overcome various complications in an infected children.
Primary infection with HSV-2 acquired by women during 
pregnancy accounts for two-thirds of the morbidity and mortality 
from HSV-2 among neonates while the rest results from reactivation 
of an old infection [27,28]. Despite the higher risk of transmission 
of HSV from mother experiencing first episode of genital herpes, 
most neonates are infected because of asymptomatic viral shedding 
and undiagnosed disease of the mother. Both these reasons make it 
important to determine the predominant HSV antibody type. In this 
study, the prevalence of anti-HSV IgM antibodies among pregnant 
women was 11.7% comparable to data from Aligarh (16.8%) [27]. 
Reports from Varanasi (33.6%) show higher prevalence, whereas 
Rajkot (2%), Mumbai (3.6%), and Lucknow (3.3%) document 
the lower prevalence of HSV IgM [14,1,15,26]. Although, a 
1982, American study reveals that despite frequent recurrences 
of genital HSV infection during pregnancy, if delivery is done 
through ceserian section, the outcome in their infants are reliably 
better [29]. Studies suggest that primary HSV infection occurring 
in first or second trimester causes an increase in spontaneous 
abortion or prematurity and fetal growth restriction [30]. An 
antenatal screening for HSV among the pregnant women is, 
therefore, required for carrying out effective interventions on 
delivery and in the lifestyle practices.
In the present study, a coinfection rate of 15.4% was 
found to be 2-fold higher compared to a study from Rajkot 
(7%) and Bengaluru (6.8%) [1,4]. A 0.9% rate of triple 
infection (rubella+CMV+Toxoplasma) seropositivity was 
comparable with 1.1% infection rate reported from Bengaluru 
(Toxoplasma+CMV+HSV) [4]. Mixed infection with TORCH 
complex has a very unfavorable outcome, and these cases have 
to be, especially, kept in mind by obstetricians when pregnant 
patients with BOH present to them.
CONCLUSION
All antenatal cases with BOH should be routinely screened for 
TORCH. Early diagnosis and appropriate intervention will 
help in proper management of these patients. Finally, the high 
seroprevalence of these agents, in our society, calls for the 
need for preventive strategies such as reproductive hygiene and 
immunization for circumventing the otherwise inevitable fetal 
outcomes. In developed nations such as France, a structural 
antenatal screening program to identify specified infections 
and instituting appropriate intervention is part of their national 
healthcare delivery system. In India, this aspect of health care has 
not received the attention it deserves, especially in the context 
of high birth rate and population growth. Effective programs 
to ensure maternal and fetal health would greatly contribute to 
population control measures and maintaining equilibrium. One 
of the pre-requisites for implementation of an effective control 
program is the availability of accurate data generated through 
long-term studies. Data reported in the present study are a small 
contribution toward this end.
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